(Circulation. 1995;92:944-949.)
© 1995 American Heart Association, Inc.
Articles |
Maintenance of Coronary Patency After Fibrinolysis With Tissue Factor Pathway Inhibitor
From the Cardiovascular Division, Washington University School of Medicine, St Louis, Mo.
Correspondence to Dana R. Abendschein, PhD, Washington University School of Medicine, Cardiovascular Division, PO Box 8086, 660 S Euclid Ave, St Louis, MO 63110.
Background Pharmacological coronary fibrinolysis induces procoagulant effects that contribute to delayed recanalization and early reocclusion. This study was designed to determine whether brief inhibition of activation of the coagulation cascade with tissue factor pathway inhibitor, a physiological inhibitor of activated factor X and its activation by the tissue factor/factor VII complex, would facilitate fibrinolysis, sustain patency of recanalized arteries, or both.
Methods and Results Platelet-rich coronary thrombi were induced with anodal current that elicited intimal injury in 21 conscious dogs. Each was randomized to human recombinant tissue-type plasminogen activator (rTPA 1.0 mg/kg IV over 1 hour) with infusion of 50 µg · kg-1 · min-1 of human recombinant tissue factor pathway inhibitor (rTFPI, n=7), 100 µg · kg-1 · min-1 of rTFPI (n=8), or 300 mmol/L arginine phosphate buffer as a control (n=6) concomitant with and for 1 hour after infusion of the plasminogen activator. Recanalization, verified with proximal Doppler flow probes, occurred in all but 1 dog given the high dose of rTFPI. It was not accelerated by conjunctive rTFPI. Reocclusion occurred within 90 minutes after infusion of rTPA in all 6 control dogs. However, reocclusion was delayed and patency was sustained for the entire 24-hour observation interval in 2 of 6 dogs (excluding 1 that did not survive) given the low dose and in 4 of 6 dogs (excluding 1 that did not receive the desired amount) given the high dose of rTFPI (P<.05 compared with controls). Cyclic flow variations indicative of platelet aggregation and disaggregation locally were virtually eliminated by rTFPI (3±4[SD]/h in dogs given the low dose and 2±2/h in those given the high dose of rTFPI compared with 13±12/h in controls, P<.05). In addition, rTFPI increased activated partial thromboplastin time and prothrombin time only at the high dose (1.4±0.3 and 2.1±0.9 times baseline) and had no effects on platelet aggregation assayed ex vivo and only minimal effects on bleeding time assayed in vivo.
Conclusions Brief inhibition of the coagulation system by administration of rTFPI sustains patency of arteries recanalized by pharmacological fibrinolysis without markedly perturbing hemostatic mechanisms.
Key Words: thrombolysis • plasminogen activators • anticoagulants
This article has been cited by other articles:
 |
|
 |
|
  Y. Zhao, S. Zhou, and C.-K. Heng Impact of Serum Amyloid A on Tissue Factor and Tissue Factor Pathway Inhibitor Expression and Activity in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1645 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. M. Moons, R. J. G. Peters, N. R. Bijsterveld, J. J. Piek, M. H. Prins, G. P. Vlasuk, W. E. Rote, and H. R. Buller Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2147 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H.M Moons, M. Levi, and R. J.G Peters Tissue factor and coronary artery disease Cardiovasc Res, February 1, 2002; 53(2): 313 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Reduced Tissue Factor Pathway Inhibitor-1 After Pharmacological Thrombolysis: An Epiphenomenon or Potential Culprit in Rethrombosis? Circulation, January 22, 2002; 105(3): 270 - 271. [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Abendschein, P. K. Baum, P. Verhallen, P. R. Eisenberg, M. E. Sullivan, and D. R. Light A Novel Synthetic Inhibitor of Factor Xa Decreases Early Reocclusion and Improves 24-h Patency after Coronary Fibrinolysis in Dogs J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 567 - 572. [Abstract] [Full Text]
|
|
|
|
|
|
M. Roque, E. D. Reis, V. Fuster, A. Padurean, J. T. Fallon, M. B. Taubman, J. H. Chesebro, and J. J. Badimon Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2303 - 2310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Badimon, M. Lettino, V. Toschi, V. Fuster, M. Berrozpe, J. H. Chesebro, and L. Badimon Local Inhibition of Tissue Factor Reduces the Thrombogenicity of Disrupted Human Atherosclerotic Plaques : Effects of Tissue Factor Pathway Inhibitor on Plaque Thrombogenicity Under Flow Conditions Circulation, April 13, 1999; 99(14): 1780 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Oltrona, C. M. Speidel, D. Recchia, S. A. Wickline, P. R. Eisenberg, and D. R. Abendschein Inhibition of Tissue Factor–Mediated Coagulation Markedly Attenuates Stenosis After Balloon-Induced Arterial Injury in Minipigs Circulation, July 15, 1997; 96(2): 646 - 652. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. McKenzie, D. R. Abendschein, and P. R. Eisenberg Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa Arterioscler. Thromb. Vasc. Biol., October 1, 1996; 16(10): 1285 - 1291. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. Antman Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial Circulation, September 1, 1996; 94(5): 911 - 921. [Abstract] [Full Text]
|
|